What is Regeneron Pharmaceuticals Price-to-Tangible-Book?
As of today (2024-04-24), Regeneron Pharmaceuticals's share price is $906.54. Regeneron Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $227.88. Hence, Regeneron Pharmaceuticals's Price to Tangible Book Ratio of today is 3.98.
The historical rank and industry rank for Regeneron Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
REGN'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.64 Med: 4.67 Max: 16.48
Current: 3.98
During the past 13 years, Regeneron Pharmaceuticals's highest Price to Tangible Book Ratio was 16.48. The lowest was 3.64. And the median was 4.67.
REGN's Price-to-Tangible-Book is ranked worse than 64.86% of 1218
companies
in the Biotechnology industry
Industry Median: 2.69
vs REGN: 3.98
A closely related ratio is called PB Ratio. As of today, Regeneron Pharmaceuticals's share price is $906.54. Regeneron Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $237.38. Hence, Regeneron Pharmaceuticals's P/B Ratio of today is 3.82.
Regeneron Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Regeneron Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regeneron Pharmaceuticals's Price-to-Tangible-Book
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Regeneron Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 